This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (40)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Preliminary Report

David T. Tse, MD; Robert C. Kersten, MD; Richard L. Anderson, MD

Arch Ophthalmol. 1984;102(7):990-994.

Abstract
• Hematoporphyrin derivative (HpD) is a photodynamically active dye that is preferentially retained by malignant tissues and initiates a cytotoxic reaction when exposed to red light. Normal tissues adjacent to a tumor retain HpD to a lesser degree and are thus spared damage from the light-induced reaction. We describe the treatment of 40 basal-cell carcinomas in three patients with nevoid basal-cell carcinoma syndrome. All treated lesions showed disappearance of clinically apparent tumor within four to six weeks, and there was no damage to surrounding skin. Thirty-three lesions (82.5%) showed complete response on biopsy findings, while seven showed residual tumor cells. The recurrence rate was 10.8%, with the follow-up ranging from 12 to 14 months. Tumor response was related to the total light dose delivered and the size and location of the tumor.

Author Affiliations
From the Division of Oculoplastics, Orbital and Oncology Services, Department of Ophthalmology, University of Iowa Hospitals and Clinics, Iowa City.

Footnotes
Accepted for publication Nov 25, 1983.

Reprint requests to the Division of Oculoplastics, Orbital and Oncology Services, Department of Ophthalmology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242 (Dr Tse).

Jane Duwa typed this manuscript. William Stwalley, PhD, Paul Kleiber, PhD, and John Bahns, PhD, Iowa Laser Facility, Iowa City, provided technical assistance. Nancy Ridenour and Jean Prybil also assisted in patient care.

This investigation was supported in part by Biomedical Research support grant RR05372 from the Biomedical Research Support Branch, Division of Research Facilities and Resources, National Institutes of Health (Dr Tse) and aided by grant IN-122 C from the American Cancer Society (Dr Tse).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Porphyrin Sensitized Phototherapy
Berns and McCullough
Arch Dermatol 1986;122:871-874.
ABSTRACT  

Hematoporphyrin Derivative Photoradiation Therapy
Taxdal
Arch Ophthalmol 1984;102:1426-1426.
ABSTRACT